|AHFS/Drugs.com||Consumer Drug Information|
|By mouth (capsules)|
|Metabolism||Hepatic (demethylation and glucuronidation)|
|Elimination half-life||1.4–2.6 hours (mesuximide)|
28–38 hours (active metabolite)
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||203.241 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Mesuximide (or methsuximide, methosuximide) is a succinimide anticonvulsant medication. It is sold as a racemate by Pfizer under the tradenames Petinutin (Switzerland) and Celontin (United States). The therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite, N-desmethylmethosuximide, which has a longer half-life and attains much higher plasma levels than its parent.
is indicated for the control of absence seizures that are refractory to other drugs.